• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

    61.87 -0.69 (-1.10%)
    Streaming Delayed Price Updated: 1:16 PM EDT, Oct 30, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about CRISPR Therapeutics AG - Common Shares

    < Previous 1 2
    ...
    11 12 13 14 15 16 17 18 19
    ...
    33 34 Next >
    3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024
    Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year. 
    Via InvestorPlace
    1 No-Brainer Stock to Buy and Hold for 10 Years
    This company has been in the news for much of the year. 
    Via The Motley Fool
    3 Growth Stocks to Buy Right Now Without Any Hesitation
    Investors shouldn't have to deliberate for too long about these great stocks. 
    Via The Motley Fool
    Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
    The major indexes ended long win streaks. Datadog led earnings winners. 
    Via Investor's Business Daily
    Why CRISPR Therapeutics Stock Could Be About to Take Off
    CRISPR's financial prospects could soon get an upgrade. 
    Via The Motley Fool
    Why CRISPR Therapeutics Stock Charged Northward This Week
    Gene correction technology took a big step forward this week. 
    Via The Motley Fool
    3 Biotech Stocks That Are Betting on the Future of Gene Editing
    These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. 
    Via InvestorPlace
    This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
    Vertex shares look cheap today considering all the company has to offer. 
    Via The Motley Fool
    3 Biotech Stocks With the Strongest Clinical Pipelines
    Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines. 
    Via InvestorPlace
    CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade
    On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier. 
    Via Investor's Business Daily
    Why you can make Vertex Pharmaceuticals a buy on any pullback
    Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely 
    Via MarketBeat
    Why CRISPR Therapeutics Stock Crushed the Market Today
    Investors were cheered by the company's latest earnings release, coupled with operational updates. 
    Via The Motley Fool
    Vertex Slouches After Tech Leader Reports Mixed Results; But Late-Stage Pipeline In Focus
    The company expects $9.85 billion in full-year sales of its cystic fibrosis treatments. 
    Via Investor's Business Daily
    Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners
    Roku vaulted 50% to become Ark Innovation's top holding. 
    Via Investor's Business Daily
    Why CRISPR Therapeutics Stock Is Moving Higher Monday
    CRISPR Therapeutics AG (NYSE: CRSP) shares are trading higher Monday after the company announced preclinical data for its investigational programs for the 
    Via Benzinga
    2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now
    These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors. 
    Via The Motley Fool
    Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
    Bulls are back in control as the major indexes confirmed the uptrend this week. 
    Via Investor's Business Daily
    Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA
    The meeting went almost as well as could be expected. 
    Via The Motley Fool
    3 Healthcare Stocks to Buy Hand Over Fist in November
    Get these stocks while they're cheap. 
    Via The Motley Fool
    One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?
    This stock could be a long-term winner, thanks to its game-changing technology. 
    Via The Motley Fool
    Why Are Stocks Up Today?
    Stocks are up today as investors prepare for the most recent information from the Federal Reserve concerning interest rates. 
    Via InvestorPlace
    Topics Economy
    Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
    Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie. 
    Via InvestorPlace
    Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug
    The agency could soon approve a potential cure for sickle cell disease . 
    Via Investor's Business Daily
    CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher?
    CRSP stock is rallying after an FDA panel appeared to view CRISPR Therapeutics' sickle-cell anemia treatment as safe. 
    Via InvestorPlace
    AMD, CRISPR Therapeutics, Paycom Software, DraftKings, Tesla: Why These 5 Stocks Are On Investors' Radars Today
    Major U.S. indices ended in the green on Tuesday, with the Dow gaining nearly 124 points or 0.4% to 33,052.87. 
    Via Benzinga
    Topics Stocks
    CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision
    Investors in CRISPR and CRSP stock have certainly been on a wild ride so far this year. Here's what investors need to watch right now. 
    Via InvestorPlace
    Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
    This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
    Via The Motley Fool
    CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy
    Although CRISPR Therapeutics may have a breakthrough drug on its hands, regulatory concerns hang over CRSP stock. 
    Via InvestorPlace
    Questions Surround Vertex/CRISPR's Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches
    The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next  
    Via Benzinga
    Vertex Pharmaceuticals: Buy at the High?
    Vertex shares have been flying high in recent times. 
    Via The Motley Fool
    < Previous 1 2
    ...
    11 12 13 14 15 16 17 18 19
    ...
    33 34 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.